AngioDynamics acquires FlowMedica renal therapy portfolio
This article was originally published in Clinica
Executive Summary
Cancer and peripheral vascular disease specialist AngioDynamics has boosted its diverse portfolio by purchasing for $1.75m in cash FlowMedica’s Benephit infusion products for delivering Targeted Renal Therapy (TRT). The deal will also see FlowMedica receive payments based on sales of Benephit systems in fiscal 2011.